Laboratory Permits, Pending FDA Approvals, Clinical Study Presentations, and Financial Results Release - Research Report on Illumina, Theravance, Acorda, Synta, and Optimer

NEW YORK, August 12, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Illumina, Inc. (NASDAQ: ILMN), Theravance, Inc. (NASDAQ: THRX), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), and Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Illumina, Inc. Research Report

On August 1, 2013, Illumina, Inc. (Illumina) announced that its subsidiary, Verinata Health (Verinata), has received the Clinical Laboratory Permit from the New York State Department of Health for its CLIA-certified CAP-accredited laboratory. The Company informed that the verifi prenatal test is now generally available in all 50 states. Dr. Jeffrey Bird, General Manager of Verinata, said, "As the first non-invasive prenatal test (NIPT) provider to receive this important certification, we can now actively serve the growing interest and demand for non-invasive prenatal testing in New York." The Full Research Report on Illumina, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-07/ILMN]

Theravance, Inc. Research Report

On August 1, 2013, Theravance, Inc. (Theravance) announced that on September 10, 2013, the FDA's Pulmonary-Allergy Drugs Advisory Committee will discuss the new molecular entity NDA 203975 for umeclidinium bromide and vilanterol dry powder for inhalation, sponsored by Glaxo Group for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). The Company informed that the Prescription Drug User Fee Act (PDUFA) goal date is December 18, 2013. The Full Research Report on Theravance, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-07/THRX]

Acorda Therapeutics, Inc. Research Report

On August 1, 2013, Acorda Therapeutics, Inc. (Acorda) reported its Q2 2013 financial results. In Q2 2013, the Company generated total revenues of $87.1 million, representing a growth of 15.1% YoY. Acorda's GAAP net income came in at $3.9 million, or $0.09 per diluted share, compared with $4.5 million, or $0.11 per diluted share, in Q2 2012. "AMPYRA sales rebounded strongly in the second quarter, as expected, based on underlying product demand and a return to normal inventory levels by the end of the first quarter," said Ron Cohen, M.D., President and CEO of Acorda. "We are reiterating our full-year AMPYRA net revenue guidance of $285-$315 million." The Full Research Report on Acorda Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-07/ACOR]

Synta Pharmaceuticals Corp. Research Report

On August 7, 2013, Synta Pharmaceuticals Corp. (Synta) announced that the results from an interim survival analysis of the GALAXY-1 trial will be presented at the 2013 Best of ASCO Meetings in Chicago on August 10, 2013; in Los Angeles on August 17, 2013; and in Boston on August 24, 2013. The Company informed that GALAXY-1 is a global, randomized Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead drug candidate, ganetespib, as second-line treatment for patients with advanced non-small cell lung adenocarcinoma. The Full Research Report on Synta Pharmaceuticals Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-08/SNTA]

Optimer Pharmaceuticals, Inc. Research Report

On August 1, 2013, Optimer Pharmaceuticals, Inc. (Optimer) reported unaudited financial results for Q2 2013. In Q2 2013, the Company generated total net revenues of $20.1 million, down 59.7% YoY. The Company informed that net revenues in Q2 2012 included $32.4 million in up-front and milestone payments under the Optimer's collaboration and license agreements with Astellas Japan and Astellas Pharma Europe. Q2 2013 net loss was $26.9 million, or $0.55 per share, compared with net loss of $0.3 million, or $0.01 per share, in Q2 2012. The Full Research Report on Optimer Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-08/OPTR]

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Investors' Reports